Trump Accelerates Psychedelic Therapy Research in the UK

In a significant move for the burgeoning psychedelic industry, President Trump signed an executive order aimed at expediting the review of psychedelic therapies, as well as increasing federal research funding. This order, which took place on April 18, marks a pivotal shift from fringe science to a more mainstream pharmaceutical opportunity, particularly concerning treatments for psychiatric conditions.

The executive order received notable attention during a ceremony at the Oval Office, attended by Joe Rogan and Health Secretary Robert F Kennedy Jr. Industries that produce substances like psilocybin, LSD, and MDMA are now viewed as potentially lucrative markets. Shares in Compass Pathways, a UK-based company leading research in psychedelics, rose sharply following the announcement. Investors are now optimistic about what could be a $50 billion market, as forecasted by Cantor Fitzgerald.

CEO Kabir Nath of Compass Pathways expressed that the executive order has alleviated some of the political risks previously surrounding this nascent market. With partnerships in place, including one with King’s College London, Compass is poised for further trials and has aligned with a UK contract manufacturer for anticipated exports to the US.

Other key players in the sector, such as AtaiBeckley, have also seen significant stock gains, reflecting a renewed interest in psychedelic therapies from major pharmaceutical companies. AtaiBeckley emerged from a substantial merger last year and is focusing on advanced treatment methodologies, such as a novel formulation of mebufotenin, which has gained FDA breakthrough designation.

Trump’s administration aims to accelerate access to innovative mental health treatments. The new directive instructs the Food and Drug Administration (FDA) to prioritise psychedelic drugs that qualify for “breakthrough therapy” status, which may shorten review times significantly. Analysts at various firms have commented on the long-term implications of this order, viewing it as an important endorsement for the psychedelic sector.

Despite the optimism, challenges still loom. The industry must navigate cultural stereotypes, the complexities of treatment implementation, and market volatility. The AdvisorShares Psychedelics ETF has seen a decline of approximately 80 percent since its launch in 2021, mirroring the struggles faced by many firms in the sector, including AtaiBeckley and Compass Pathways.

Discussion around the medical use of psychedelics continues, especially in the UK, where opinions among healthcare experts vary. Some caution that the long-term effects of psychedelic usage remain inadequately researched. Ongoing dialogue is essential as professionals aim to bridge the gap between mental and physical health treatments, striving to ensure efficacy and safety in future applications of these substances.

As the landscape evolves, the world will be watching how these developments unfold in both the US and the UK markets.